Joseph R. Aiello, M.D.

Joseph R. Aiello, M.D.

Education:

  • 1996-1998 University of North Carolina, Chapel Hill
    Fellowship, Nephrology
  • 1995-1996 University of North Carolina, Chapel Hill
    Chief Resident, Internal Medicine
  • 1993-1995 University of North Carolina, Chapel Hill
    Residency, Internal Medicine
  • 1988-1992 Georgetown University
    Doctor of Medicine
  • 1984-1988 Georgetown University
    Bachelor of Science

Work Experience:

  • 1998-Present Clinical Nephrologist
    Mountain Kidney and Hypertension Associates, PA
  • 1996-1998 Fellow in Nephrology
    University of North Carolina, Chapel Hill
  • 1993-1996 Medical Residency, Internal Medicine
    University of North Carolina, Chapel Hill

Credentials:

  • Medical License: North Carolina Physician License - 9500006
  • Certification: North Carolina Medical Board - 54659
    American Board of Internal Medicine, 1996, 2006
    American Board of Nephrology, 1999, 2008

Hospital Affiliations:

  • 1998-Present Mission-St. Joseph's Health System
    509 Biltmore Avenue
    Asheville, NC 28801-4690

Professional Affiliations / Committees:

  • American Society of Nephrology
  • International Society of Nephrology
  • National Kidney Foundation
  • Renal Physicians Association
  • North Carolina Medical Society
  • Buncombe County Medical Society

Research:

  • A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using XXXX and XXXX in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of XXXX for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease
  • A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with XXXX
  • A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of XXXX vs. Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
  • A Phase 4, Long-Term Observational Safety Study in End Stage Renal Disease Subjects Treated with XXXX
  • A Phase 3, Randomized, Active-Controlled, Open-Label Study of the Safety and Efficacy of XXXX Injection for the Correction of Anemia in Patients with Chronic Renal Failure not on Dialysis and not on Erythropoiesis Stimulating Agent (ESA) Treatment
  • An Open-Label, Single-Arm Study to Assess the Safety of XXXX Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease
  • Trial to Reduce Cardiovascular Events with XXXX Therapy
  • A Multi-Center, Single-Arm Study Evaluating De Novo Once Every Two Weeks XXXX Dosing in Subjects with Chronic Kidney Disease Not Receiving Dialysis
  • A Multi-Center, Single-Arm Study Evaluating Once Monthly XXXX Dosing in Subjects with Chronic Kidney Disease Not Receiving Hemodialysis
  • Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects with Anemia
  • A Study of XXXX Administered Once Every Four Weeks in Chronic Renal Insufficiency (CRI) Subjects with Anemia
  • An Open-Label, Randomized, Multi-Center Phase 3, Comparator Controlled Parallel Group Study to Assess the Long-Term Safety and Efficacy of XXXX in Chronic Renal Failure Patients Receiving Hemodialysis